Torsdag 31 Oktober | 15:24:03 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-05-14 - Årsstämma
2025-01-22 08:00 Bokslutskommuniké 2024
2024-10-16 - Kvartalsrapport 2024-Q3
2024-07-17 - Kvartalsrapport 2024-Q2
2024-07-12 - Split FLERIE 100:1
2024-05-14 - Årsstämma
2024-05-08 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2024-04-15 - Kvartalsrapport 2024-Q1
2024-01-24 - Bokslutskommuniké 2023
2023-11-28 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-24 - Kvartalsrapport 2023-Q1
2023-05-24 - Årsstämma
2023-05-08 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2023-02-23 - Bokslutskommuniké 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-02 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2022-06-01 - Årsstämma
2022-05-16 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-06-04 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2021-06-03 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2021-01-12 - Extra Bolagsstämma 2020
2020-11-25 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-21 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2020-04-20 - Årsstämma
2020-02-20 - Bokslutskommuniké 2019
2019-11-27 - Kvartalsrapport 2019-Q3
2019-10-09 - Extra Bolagsstämma 2019
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-07 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-05-06 - Årsstämma
2019-02-20 - Bokslutskommuniké 2018
2018-11-19 - Kvartalsrapport 2018-Q3
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-31 - X-dag ordinarie utdelning FLERIE 0.00 SEK
2017-05-30 - Årsstämma
2017-05-30 - Kvartalsrapport 2017-Q1
2017-02-27 - Bokslutskommuniké 2016
2016-11-22 - Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Flerie är en aktiv långsiktig life science-investerare med fokus på bioteknik- och läkemedelsinvesteringar globalt. Bolaget är baserat i Stockholm och London och förvaltar en portfölj med investeringar i Europa, Israel och USA. Huvudfokus ligger på att förse organisationer som främst verkar inom läkemedelsutveckling, med tjänster och resurser. Flerie grundades 2011 och har sitt huvudkontor i Stockholm.
2024-07-17 08:00:00

April – June 2024
· Net asset value was SEK 4,380 million (3,511) and net asset value per share was SEK 56.10 (57.80), adjusted net asset value per share was SEK 57.41 (57.80)
· Change in net asset value per share was -0.3 per cent (-1.1), adjusted change in net asset value per share was 2.1 per cent
· Total fair value of shares in portfolio companies was SEK 3,058 million (3,041)
· Change in fair value of shares in portfolio companies was SEK 172 million (-58), equivalent to 6.2 per cent (-2.0).
· Net profit/loss amounted to SEK 103 million (-38)
· Profit per share before and after dilution amounted to SEK 1.59 (-0.63)
· Net sales was SEK 0.1 million (-)

January – June 2024
· Change in net asset value per share was -4.4 per cent (5.4), adjusted change in net asset value per share was -2.2 per cent
· Change in fair value of shares in portfolio companies was SEK 19 million (2), equivalent to 0.7 per cent (0.1).
· Net profit/loss amounted to SEK -47 million (-38)
· Profit per share before and after dilution amounted to SEK -0.75 (-0.07)
· The expense ratio amounted to 1.3 per cent (1.2)
· Cash and cash equivalents amounted to SEK 882 million (355)
· Net sales was SEK 0.1 million (-)

Significant events during the quarter
· In May, an agreement was entered into between Flerie Invest and Flerie AB (former InDex Pharmaceuticals) to carry out a reverse merger. The transaction was closed in June and brought SEK 223 million of cash to Flerie Invest. In June a directed share issue was carried out which brought the Company circa SEK 607 million before transaction costs.
· Investments in the Product Development segment was SEK 135 million.
· At an EGM in June, it was decided to introduce a share redemptionprogram. The program enables an annual redemption of up to five percent of the share capital with Q2 2025 as the first redemption opportunity.
· On June 27, Flerie's shares began trading on Nasdaq Stockholm.
· XNK Therapeutics was declared bankrupt on 8 April. The full value of the company was written down during the first quarter, equivalent to SEK 59 million.

Shareholders, financial analysts and media are kindly invited to a webcast in English, including presentation of the quarterly results and a Q&A, today the 17th of July 2024 at 14:00 CET.

Please register via the link below. Note that it can take several minutes to receive the confirmation email with the teams link.
Microsoft Virtual Events Powered by Teams

The presentation will be available after the webcast at Flerie.com.